Original language | English |
---|---|
Journal | Nature Reviews Drug Discovery |
Volume | 22 |
Issue number | 8 |
Pages (from-to) | 605-606 |
Number of pages | 2 |
ISSN | 1474-1776 |
DOIs |
|
Publication status | Published - 2023 |
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
eTRANSAFE : data science to empower translational safety assessment. / Sanz, Ferran; Pognan, François; Steger-Hartmann, Thomas; Díaz, Carlos; Asakura, Shoji; Amberg, Alexander; Bécourt-Lhote, Nathalie; Blomberg, Niklas; Bosc, Nicolas; Briggs, Katharine; Bringezu, Frank; Brulle-Wohlhueter, Claire; Brunak, Søren; Bueters, Ruud; Callegaro, Giulia; Capella-Gutierrez, Salvador; Centeno, Emilio; Corvi, Javier; Cronin, Mark T.D.; Drew, Philip; Duchateau-Nguyen, Guillemette; Ecker, Gerhard F.; Escher, Sylvia; Felix, Eloy; Ferreiro, Miguel; Frericks, Markus; Furlong, Laura I.; Geiger, Robert; George, Catherine; Grandits, Melanie; Ivanov-Draganov, Dragomir; Kilgour-Christie, Jean; Kiziloren, Tevfik; Kors, Jan A.; Koyama, Naoki; Kreuchwig, Annika; Leach, Andrew R.; Mayer, Miguel Angel; Monecke, Peter; Muster, Wolfgang; Nakazawa, Chihiro Miyamoto; Nicholson, Gavin; Parry, Rowan; Pastor, Manuel; Piñero, Janet; Oberhauser, Nils; Ramírez-Anguita, Juan Manuel; Rodrigo, Adrián; Smajic, Aljosa; Schaefer, Markus; Schieferdecker, Sebastian; Soininen, Inari; Terricabras, Emma; Trairatphisan, Panuwat; Turner, Sean C.; Valencia, Alfonso; van de Water, Bob; van der Lei, Johan L.; van Mulligen, Erik M.; Vock, Esther; Wilkinson, David.
In: Nature Reviews Drug Discovery, Vol. 22, No. 8, 2023, p. 605-606.Research output: Contribution to journal › Comment/debate › Research
}
TY - JOUR
T1 - eTRANSAFE
T2 - data science to empower translational safety assessment
AU - Sanz, Ferran
AU - Pognan, François
AU - Steger-Hartmann, Thomas
AU - Díaz, Carlos
AU - Asakura, Shoji
AU - Amberg, Alexander
AU - Bécourt-Lhote, Nathalie
AU - Blomberg, Niklas
AU - Bosc, Nicolas
AU - Briggs, Katharine
AU - Bringezu, Frank
AU - Brulle-Wohlhueter, Claire
AU - Brunak, Søren
AU - Bueters, Ruud
AU - Callegaro, Giulia
AU - Capella-Gutierrez, Salvador
AU - Centeno, Emilio
AU - Corvi, Javier
AU - Cronin, Mark T.D.
AU - Drew, Philip
AU - Duchateau-Nguyen, Guillemette
AU - Ecker, Gerhard F.
AU - Escher, Sylvia
AU - Felix, Eloy
AU - Ferreiro, Miguel
AU - Frericks, Markus
AU - Furlong, Laura I.
AU - Geiger, Robert
AU - George, Catherine
AU - Grandits, Melanie
AU - Ivanov-Draganov, Dragomir
AU - Kilgour-Christie, Jean
AU - Kiziloren, Tevfik
AU - Kors, Jan A.
AU - Koyama, Naoki
AU - Kreuchwig, Annika
AU - Leach, Andrew R.
AU - Mayer, Miguel Angel
AU - Monecke, Peter
AU - Muster, Wolfgang
AU - Nakazawa, Chihiro Miyamoto
AU - Nicholson, Gavin
AU - Parry, Rowan
AU - Pastor, Manuel
AU - Piñero, Janet
AU - Oberhauser, Nils
AU - Ramírez-Anguita, Juan Manuel
AU - Rodrigo, Adrián
AU - Smajic, Aljosa
AU - Schaefer, Markus
AU - Schieferdecker, Sebastian
AU - Soininen, Inari
AU - Terricabras, Emma
AU - Trairatphisan, Panuwat
AU - Turner, Sean C.
AU - Valencia, Alfonso
AU - van de Water, Bob
AU - van der Lei, Johan L.
AU - van Mulligen, Erik M.
AU - Vock, Esther
AU - Wilkinson, David
N1 - Funding Information: Drug safety is not the main domain for competition between pharmaceutical companies, and so it is more feasible to develop collaborative projects in this area. For example, legacy drug safety data may be shared among companies with the aim of improving drug safety assessment. Significant steps forward in this direction were taken by the eTOX and eTRANSAFE projects. The eTOX project , which focused on sharing preclinical toxicological data, was carried out from 2010 to 2017. More recently, the eTRANSAFE project , addressing translational drug safety assessment through integrative knowledge management, has been running from 2017 to 2023. Both projects are part of the Innovative Medicines Initiative (IMI) funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Here, we highlight the achievements of the eTRANSAFE initiative and discuss the impact of the tools it has developed.
PY - 2023
Y1 - 2023
U2 - 10.1038/d41573-023-00099-5
DO - 10.1038/d41573-023-00099-5
M3 - Comment/debate
C2 - 37316648
AN - SCOPUS:85161815073
VL - 22
SP - 605
EP - 606
JO - Nature Reviews. Drug Discovery
JF - Nature Reviews. Drug Discovery
SN - 1474-1776
IS - 8
ER -